Abstract:Pulmonary vascular disease is a broad category of disorders threatening millions of people in the world, often leading to abnormal blood flow between the lungs and heart. Despite multiple drugs interfering with prostacyclin, endothelin, nitric oxide pathways were available for pulmonary arterial hypertension (PAH) over the past 15 years, it still remained severe and complicated clinical situation (Humbert et al., 2019). The new prevention and treatment strategies for PAH are a major clinical issue as well as a scientific challenge that needed to be addressed urgently. Discovery in pathobiological and cellular mechanisms of pulmonary vascular remodeling will promote the progression of PAH. We organized the Research Topic entitled “Drug Development and Target Discovery in Pulmonary Vascular Diseases” to discuss and explore new therapeutic targets and mechanism of drug action toward pulmonary vascular disease. The topic covers both basic scientific as well as clinical aspects, consisting 4 original research articles and 1 abstract. Our Research Topic has been well received by the readership of the journal with over 5,000 views and more than 1,000 article downloads. The feature of PAH is involved in the reduction of prostacyclin synthase expression and disorder of prostacyclin metabolic pathway. The clinical uses of prostacyclin analogues mimic endogenous prostacyclin, which lead to vasodilation and improvement of vascular remodeling (Galiè et al., 2003; Galiè et al., 2016). As a member of the prostacyclin family, iloprost was used for severe PAH and acute right ventricular (RV) failure. The importance for RV physiological changes during acute iloprost inhalation is discussed in the paper of Li et al. By cardiovascular magnetic resonance imaging, authors showed that acute iloprost inhalation increased RV ejection fraction and RV stroke volume, as well as decreased RV volume in idiopathic PAH and connective tissues disease associated PAH. These observations suggested RV function improvement would be largely attribute to a reduction of afterload by iloprost. This knowledge further added the clinical pharmacological value of iloprost for treatment of PAH. As a mainstay of contemporary treatment, prostacyclin analogues therapies have been recommended to improve heamodynamics and outcomes in short term trials. (Barst et al., 1996). Beraprost is another chemically stable and orally active prostacyclin analogue. However, their present action mechanisms do not explain the relationship between their receptor subtype and ion

Inhaled Iloprost for the Treatment of Primary Pulmonary Hypertension

Hemodynamic And Gas Exchange Effects Of Inhaled Iloprost In Patients With Copd And Pulmonary Hypertension

[Efficacy of Inhaled Iloprost on Top of Other Targeted Therapies for Patients with Pulmonary Hypertension and Severe Right Heart Failure].

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost

Autologous Endothelial Progenitor Cells Transplantation for the Therapy of Primary Pulmonary Hypertension

Effect of Inhaled Iloprost on Pulmonary Hypertension Related to Congenital Heart Disease After Cardiopulmonary Bypass

Iloprost for Children with Pulmonary Hypertension after Surgery to Correct Congenital Heart Disease

GW25-e5415 Effects of Inhaled Iloprost on Gas Exchange and Hemodynamics in Patients with Pulmonary Hypertension Due to Lung Diseases

Inhaled pulmonary vasodilators: a narrative review

Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn

Peri-Operative Pulmonary Hypertension in Paediatric Patients: Current Strategies in Children with Congenital Heart Disease

Comparison of Inhaled Nitric Oxide and Iloprost in Infants with Moderate or Severe Pulmonary Hypertension Af-Ter Cardiac Surgery:A Prospective Randomized Trial

Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension

A Prostacyclin Analogue, Iloprost, Protects from Bleomycin-Induced Pulmonary Fibrosis in Mice

Intravenous Iloprost Treatment for Patients Underwent Total Cavopulmonary Connection in the Early Postoperative Period

Intravenous infusion of autologous endothelial progenitor cells in treatment of primary pulmonary hypertension

Advances in the Study of Inhaled Formulations for the Treatment of Pulmonary Arterial Hypertension

Effectiveness and safety of intravenous iloprost for severe persistent pulmonary hypertension of the newborn

Advances in the potential of nebulized inhalation for the treatment of pulmonary arterial hypertension

Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases

Progress in Pharmacological Treatment of Pulmonary Arterial Hypertension